Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHERYL A HULL

Allopathic & Osteopathic Physicians Dermatology

NPI
1124081849
CMS profile
142103
Location
ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$627.01

26 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHERYL A HULL

NPI 1124081849 · CMS profile ID 142103

Allopathic & Osteopathic Physicians / Dermatology

ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124081849?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124081849?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124081849?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1124081849?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

26 matching records · $627.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 26 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–26 of 26.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $15.6912/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812725025 CMS
AbbVie Inc. $11.3712/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794889160 CMS
Lilly USA, LLC $16.7411/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818901333 CMS
Allergan, Inc. $1.7310/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792811357 CMS
Janssen Biotech, Inc. $17.8610/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787871637 CMS
Janssen Biotech, Inc. $15.9210/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787871641 CMS
Novartis Pharmaceuticals Corporation $15.6910/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812725023 CMS
AbbVie Inc. $19.3510/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794889157 CMS
Galderma Laboratories, L.P. $12.2608/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855280927 CMS
AbbVie Inc. $12.9208/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794889153 CMS
Regeneron Healthcare Solutions, Inc. $21.2107/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809588295 CMS
GENZYME CORPORATION $99.2807/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843583011 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $20.9407/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869049 CMS
Novartis Pharmaceuticals Corporation $11.5507/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812725021 CMS
Novartis Pharmaceuticals Corporation $16.0406/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812725019 CMS
Lilly USA, LLC $13.7406/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819004169 CMS
Bausch Health US, LLC $45.0006/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851556955 CMS
AbbVie Inc. $12.1406/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794889149 CMS
Janssen Biotech, Inc. $15.1005/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787871647 CMS
Lilly USA, LLC $16.9205/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819007309 CMS
AbbVie Inc. $13.8105/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794889145 CMS
GENZYME CORPORATION $13.2905/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843582981 CMS
Allergan, Inc. $12.5405/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792811353 CMS
AbbVie Inc. $14.9604/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794889141 CMS
Allergan, Inc. $143.2503/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792811349 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $17.7101/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869047 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,430.05 27
PY2020 $231.11 11
PY2021 $627.01 26
PY2022 $517.89 25
PY2023 $1,474.67 21
PY2024 $880.69 32
PY2025 $676.63 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $380,038.55 259
PY2024 Principal investigator $408,860.46 382
PY2023 Principal investigator $228,849.11 170
PY2022 Recipient $321.00 1
PY2022 Principal investigator $248,165.36 66
PY2021 Recipient $2,700.00 2
PY2021 Principal investigator $244,500.15 37
PY2020 Recipient $643.47 2
PY2020 Principal investigator $251,307.20 46
PY2019 Recipient $4.75 1
PY2019 Principal investigator $990,287.65 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,050.12 12/31/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792488919
Principal investigator 1 ABBVIE INC. $46.18 12/31/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
IMMprint: A Phase 3b Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study Evaluating Safety and Efficacy of Risankizumab Compared to Placebo in Adult Subjects with Moderate to Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement (PPPsO) No dispute reported 06/30/2026 792488999
Principal investigator 1 Bausch Health US, LLC $12,505.00 12/22/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850496908
Principal investigator 1 ABBVIE INC. $1,741.20 11/17/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
IMMprint: A Phase 3b Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study Evaluating Safety and Efficacy of Risankizumab Compared to Placebo in Adult Subjects with Moderate to Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement (PPPsO) No dispute reported 06/30/2026 792482917
Principal investigator 1 Bausch Health US, LLC $24,475.00 11/05/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850496889
Principal investigator 1 ABBVIE INC. $1,380.60 11/04/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792481067
Principal investigator 1 Bausch Health US, LLC $13,700.00 09/17/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850496871
Principal investigator 1 Bausch Health US, LLC $9,915.00 08/20/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850496853
Principal investigator 1 Bausch Health US, LLC $3,000.00 07/30/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850496835
Principal investigator 1 ABBVIE INC. $1,745.40 07/29/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792469001
Principal investigator 1 ABBVIE INC. $3,456.00 06/30/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792464523
Recipient Bausch Health US, LLC $1,000.00 06/07/2021 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850474755
Principal investigator 1 Eli Lilly and Company $27.25 05/03/2021 Non-covered Recipient Entity
PONCE SCHOOL OF MEDICINE
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819465195
Principal investigator 1 Eli Lilly and Company $50.00 04/30/2021 Non-covered Recipient Entity
RALEIGH NEUROLOGY ASSOCIATES
PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND, SINGLE-ASCENDING DOSE AND REPEAT-DOSE TRIAL IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 819463721
Recipient Bausch Health US, LLC $1,700.00 04/19/2021 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850474794
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,035.14 04/06/2021 Non-covered Recipient Entity
Dr Cheryl Hull
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 819893767
Principal investigator 1 Eli Lilly and Company $16.65 04/01/2021 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819448297
Principal investigator 1 Eli Lilly and Company $25.50 04/01/2021 Non-covered Recipient Entity
ALLCUTIS RESEARCH INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819451735
Principal investigator 1 Eli Lilly and Company $48.20 04/01/2021 Non-covered Recipient Entity
CINCINNATI RHEUMATIC DISEASE STUDY GROUP INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819453751
Principal investigator 1 Eli Lilly and Company $27.15 04/01/2021 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819455083
Principal investigator 1 Eli Lilly and Company $20.25 04/01/2021 Non-covered Recipient Entity
COVANCE CLINICAL RESEARCH UNIT INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819455679
Principal investigator 1 Eli Lilly and Company $4.50 04/01/2021 Non-covered Recipient Entity
DERMATOLOGY RESEARCH ASSOCIATES INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819456377
Principal investigator 1 Eli Lilly and Company $4.50 04/01/2021 Non-covered Recipient Entity
LUIS RIVERA-COLON, MD
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819459437
Principal investigator 1 Eli Lilly and Company $24.30 04/01/2021 Non-covered Recipient Entity
HIGHLANDS ONCOLOGY GROUP PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819460369
Principal investigator 1 Eli Lilly and Company $4.50 04/01/2021 Non-covered Recipient Entity
LCGK RSRCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819462165
Principal investigator 1 Eli Lilly and Company $176.45 04/01/2021 Non-covered Recipient Entity
MARIETTA DERMATOLOGY CLINCAL RESEARCH INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819462253
Principal investigator 1 Eli Lilly and Company $38.25 04/01/2021 Non-covered Recipient Entity
PAUL NORWOOD MD DBA VALLEY RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819463815
Principal investigator 1 Eli Lilly and Company $94,122.00 03/10/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819463987
Principal investigator 1 Janssen Research & Development, LLC $1,280.40 03/05/2021 Non-covered Recipient Entity
Nw Arkansas Clnc Trials Ctr Pllc
A Multi Center open registry of patients with psoriasis who are candidates for systematic therapy including biologics No dispute reported 06/30/2026 787719305
Principal investigator 1 ABBVIE INC. $1,345.80 03/02/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792426705
Principal investigator 1 Bausch Health US, LLC $2,300.00 03/01/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850496821
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,783.80 02/16/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EXTENSION STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 800638109
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,029.02 02/09/2021 Non-covered Recipient Entity
Dr Cheryl Hull
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 819893761
Principal investigator 1 Eli Lilly and Company $200.00 01/29/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND, SINGLE-ASCENDING DOSE AND REPEAT-DOSE TRIAL IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 819461141
Principal investigator 1 ABBVIE INC. $1,345.80 01/28/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792413105
Principal investigator 1 Bausch Health US, LLC $6,955.00 01/25/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850496801
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,212.50 01/15/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A RANDOMIZED DOUBLE BLIND MULTI CENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNSHINE No dispute reported 06/30/2026 800638101
Principal investigator 1 Novartis Pharmaceuticals Corporation $16.49 01/15/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF SUBCUTANEOUS SECUKINUMAB IN SUBJECTS OF BODY WEIGHT 90 KG OR HIGHER WITH MODERATE TO SEVERE CHRONIC PLAQUE TYPE PSORIASIS No dispute reported 06/30/2026 800638115
Principal investigator 1 Eli Lilly and Company $2,392.20 01/04/2021 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 819462863